Apogee Therapeutics’ APG777 Demonstrates Promising Longevity in Phase 1 Study, Ahead of Key 2025 Milestones
Nine-Month Follow-Up Data Validates APG777's Extended Half-Life and Safety, as Investors Look to Pipeline Updates and Upcoming Clinical Data In ...



















